Cargando…

N6-methyladenosine-dependent signalling in cancer progression and insights into cancer therapies

The N6-methyladenosine (m6A) modification is a dynamic and reversible epigenetic modification, which is co-transcriptionally deposited by a methyltransferase complex, removed by a demethylase, and recognized by reader proteins. Mechanistically, m6A modification regulates the expression levels of mRN...

Descripción completa

Detalles Bibliográficos
Autores principales: Tan, Fenghua, Zhao, Mengyao, Xiong, Fang, Wang, Yumin, Zhang, Shanshan, Gong, Zhaojian, Li, Xiayu, He, Yi, Shi, Lei, Wang, Fuyan, Xiang, Bo, Zhou, Ming, Li, Xiaoling, Li, Yong, Li, Guiyuan, Zeng, Zhaoyang, Xiong, Wei, Guo, Can
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8082653/
https://www.ncbi.nlm.nih.gov/pubmed/33926508
http://dx.doi.org/10.1186/s13046-021-01952-4
_version_ 1783685882983743488
author Tan, Fenghua
Zhao, Mengyao
Xiong, Fang
Wang, Yumin
Zhang, Shanshan
Gong, Zhaojian
Li, Xiayu
He, Yi
Shi, Lei
Wang, Fuyan
Xiang, Bo
Zhou, Ming
Li, Xiaoling
Li, Yong
Li, Guiyuan
Zeng, Zhaoyang
Xiong, Wei
Guo, Can
author_facet Tan, Fenghua
Zhao, Mengyao
Xiong, Fang
Wang, Yumin
Zhang, Shanshan
Gong, Zhaojian
Li, Xiayu
He, Yi
Shi, Lei
Wang, Fuyan
Xiang, Bo
Zhou, Ming
Li, Xiaoling
Li, Yong
Li, Guiyuan
Zeng, Zhaoyang
Xiong, Wei
Guo, Can
author_sort Tan, Fenghua
collection PubMed
description The N6-methyladenosine (m6A) modification is a dynamic and reversible epigenetic modification, which is co-transcriptionally deposited by a methyltransferase complex, removed by a demethylase, and recognized by reader proteins. Mechanistically, m6A modification regulates the expression levels of mRNA and nocoding RNA by modulating the fate of modified RNA molecules, such as RNA splicing, nuclear transport, translation, and stability. Several studies have shown that m6A modification is dysregulated in the progression of multiple diseases, especially human tumors. We emphasized that the dysregulation of m6A modification affects different signal transduction pathways and involves in the biological processes underlying tumor cell proliferation, apoptosis, invasion and migration, and metabolic reprogramming, and discuss the effects on different cancer treatment.
format Online
Article
Text
id pubmed-8082653
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-80826532021-04-29 N6-methyladenosine-dependent signalling in cancer progression and insights into cancer therapies Tan, Fenghua Zhao, Mengyao Xiong, Fang Wang, Yumin Zhang, Shanshan Gong, Zhaojian Li, Xiayu He, Yi Shi, Lei Wang, Fuyan Xiang, Bo Zhou, Ming Li, Xiaoling Li, Yong Li, Guiyuan Zeng, Zhaoyang Xiong, Wei Guo, Can J Exp Clin Cancer Res Review The N6-methyladenosine (m6A) modification is a dynamic and reversible epigenetic modification, which is co-transcriptionally deposited by a methyltransferase complex, removed by a demethylase, and recognized by reader proteins. Mechanistically, m6A modification regulates the expression levels of mRNA and nocoding RNA by modulating the fate of modified RNA molecules, such as RNA splicing, nuclear transport, translation, and stability. Several studies have shown that m6A modification is dysregulated in the progression of multiple diseases, especially human tumors. We emphasized that the dysregulation of m6A modification affects different signal transduction pathways and involves in the biological processes underlying tumor cell proliferation, apoptosis, invasion and migration, and metabolic reprogramming, and discuss the effects on different cancer treatment. BioMed Central 2021-04-29 /pmc/articles/PMC8082653/ /pubmed/33926508 http://dx.doi.org/10.1186/s13046-021-01952-4 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Review
Tan, Fenghua
Zhao, Mengyao
Xiong, Fang
Wang, Yumin
Zhang, Shanshan
Gong, Zhaojian
Li, Xiayu
He, Yi
Shi, Lei
Wang, Fuyan
Xiang, Bo
Zhou, Ming
Li, Xiaoling
Li, Yong
Li, Guiyuan
Zeng, Zhaoyang
Xiong, Wei
Guo, Can
N6-methyladenosine-dependent signalling in cancer progression and insights into cancer therapies
title N6-methyladenosine-dependent signalling in cancer progression and insights into cancer therapies
title_full N6-methyladenosine-dependent signalling in cancer progression and insights into cancer therapies
title_fullStr N6-methyladenosine-dependent signalling in cancer progression and insights into cancer therapies
title_full_unstemmed N6-methyladenosine-dependent signalling in cancer progression and insights into cancer therapies
title_short N6-methyladenosine-dependent signalling in cancer progression and insights into cancer therapies
title_sort n6-methyladenosine-dependent signalling in cancer progression and insights into cancer therapies
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8082653/
https://www.ncbi.nlm.nih.gov/pubmed/33926508
http://dx.doi.org/10.1186/s13046-021-01952-4
work_keys_str_mv AT tanfenghua n6methyladenosinedependentsignallingincancerprogressionandinsightsintocancertherapies
AT zhaomengyao n6methyladenosinedependentsignallingincancerprogressionandinsightsintocancertherapies
AT xiongfang n6methyladenosinedependentsignallingincancerprogressionandinsightsintocancertherapies
AT wangyumin n6methyladenosinedependentsignallingincancerprogressionandinsightsintocancertherapies
AT zhangshanshan n6methyladenosinedependentsignallingincancerprogressionandinsightsintocancertherapies
AT gongzhaojian n6methyladenosinedependentsignallingincancerprogressionandinsightsintocancertherapies
AT lixiayu n6methyladenosinedependentsignallingincancerprogressionandinsightsintocancertherapies
AT heyi n6methyladenosinedependentsignallingincancerprogressionandinsightsintocancertherapies
AT shilei n6methyladenosinedependentsignallingincancerprogressionandinsightsintocancertherapies
AT wangfuyan n6methyladenosinedependentsignallingincancerprogressionandinsightsintocancertherapies
AT xiangbo n6methyladenosinedependentsignallingincancerprogressionandinsightsintocancertherapies
AT zhouming n6methyladenosinedependentsignallingincancerprogressionandinsightsintocancertherapies
AT lixiaoling n6methyladenosinedependentsignallingincancerprogressionandinsightsintocancertherapies
AT liyong n6methyladenosinedependentsignallingincancerprogressionandinsightsintocancertherapies
AT liguiyuan n6methyladenosinedependentsignallingincancerprogressionandinsightsintocancertherapies
AT zengzhaoyang n6methyladenosinedependentsignallingincancerprogressionandinsightsintocancertherapies
AT xiongwei n6methyladenosinedependentsignallingincancerprogressionandinsightsintocancertherapies
AT guocan n6methyladenosinedependentsignallingincancerprogressionandinsightsintocancertherapies